AR057848A1 - Diarilureas para el tratamiento de la hipertension pulmonar - Google Patents
Diarilureas para el tratamiento de la hipertension pulmonarInfo
- Publication number
- AR057848A1 AR057848A1 ARP060104766A ARP060104766A AR057848A1 AR 057848 A1 AR057848 A1 AR 057848A1 AR P060104766 A ARP060104766 A AR P060104766A AR P060104766 A ARP060104766 A AR P060104766A AR 057848 A1 AR057848 A1 AR 057848A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- independently
- alkoxy
- hydroxy
- Prior art date
Links
- 208000002815 pulmonary hypertension Diseases 0.000 title abstract 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- -1 hydrate Substances 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 abstract 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 abstract 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 abstract 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 abstract 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 abstract 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 abstract 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 abstract 2
- 229930192474 thiophene Natural products 0.000 abstract 2
- 150000003852 triazoles Chemical class 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- NQPJDJVGBDHCAD-UHFFFAOYSA-N 1,3-diazinan-2-one Chemical compound OC1=NCCCN1 NQPJDJVGBDHCAD-UHFFFAOYSA-N 0.000 abstract 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 abstract 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 abstract 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 abstract 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 abstract 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 abstract 1
- 229910003827 NRaRb Inorganic materials 0.000 abstract 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 abstract 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000005265 dialkylamine group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003248 quinolines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229960003787 sorafenib Drugs 0.000 abstract 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a composiciones farmacéuticas para el tratamiento, prevencion o control de la hipertension pulmonar que comprende al menos un compuesto de diarilurea combinado opcionalmente con al menos un agente terapéutico adicional. Combinaciones utiles incluyen, por ejemplo, BAY 43-9006 como un compuesto de diarilurea. Reivindicacion 1: Uso de un compuesto de formula (1) o una sal farmacéuticamente aceptable, polimorfo, solvato, hidrato, metabolito, profármaco o forma diastereoisomérica del mismo, para la preparacion de un medicamento para el tratamiento, prevencion o control de la hipertension pulmonar, en la que: Q es -C(O)Rx, Rx es hidroxi, alquilo C1-4, alcoxi C1-4 o NRaRb, Ra y Rb son independientemente: a) H, b) alquilo C1-4, opcionalmente sustituido con hidroxi, alcoxi C1-4, un grupo heteroarilo seleccionado de pirrol, furano, tiofeno, imidazol, pirazol, tiazol, oxazol, isoxazol, isotiazol, triazol, tetrazol, tiadiazol, oxadiazol, piridina, pirimidina, piridazina, pirazina, triazina, benzoxazol, isoquinolina, quinolinas e imidazopirimidina, un grupo heterocíclico seleccionado de tetrahidropirano, tetrahidrofurano, 1,3-dioxolano, 1,4-dioxano, morfolina, tiomorfolina, piperazina, piperidina, piperidinona, tetrahidropirimidona, sulfuro de pentametileno, sulfuro de tetrametileno, dihidropirano, dihidrofurano y dihidrotiofeno, amino, -NH2, opcionalmente sustituido con uno o dos grupos alquilo C1-4, o fenilo, c) fenilo opcionalmente sustituido con halogeno, o amino, -NH2, opcionalmente sustituido con uno o dos grupos alquilo C1-4, o d) un grupo heteroarilo seleccionado de pirrol, furano, tiofeno, imidazol, pirazol, tiazol, oxazol, isoxazol, isotiazol, triazol, tetrazol, tiadiazol, oxadiazol, piridina, pirimidina, piridazina, pirazina, triazina, benzoxazol, isoquinolina, quinolina e imidazopirimidina; A es un grupo fenilo opcionalmente sustituido de formula (2), un grupo piridinilo opcionalmente sustituido de formula (3) o una porcion naftilo opcionalmente sustituida de formula (4); B es fenilo o naftilo opcionalmente sustituidos de formulas (5) y (6), L es un grupo puente que es -S- u -O-; p es 0, 1, 2, 3 o 4; n es 0, 1, 2, 3, 4, 5 o 6; m es 0, 1, 2 o 3; cada R1 es independientemente: halogeno, haloalquilo C1-5, NO2, C(O)NR4R5, alquilo C1-6, dialquil C1-6-amina, alquil C1-3-amina, CN, amino, hidroxi o alcoxi C1-3; cada R2 es independientemente: alquilo C1-5, haloalquilo C1-5, alcoxi C1-3, N-oxo o N-hidroxi; cada R3 es independientemente: halogeno, R4, OR4, S(O)R4, C(O)R4, C(O)NR4R5, oxo, ciano o nitro (NO2) y R4 y R5 son independientemente H, alquilo C1-6, y hasta alquilo C1-6 per-halogenado.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05024508 | 2005-11-10 | ||
| EP05027449 | 2005-12-15 | ||
| EP06007775 | 2006-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057848A1 true AR057848A1 (es) | 2007-12-19 |
Family
ID=37651281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104766A AR057848A1 (es) | 2005-11-10 | 2006-10-31 | Diarilureas para el tratamiento de la hipertension pulmonar |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20090176791A1 (es) |
| EP (1) | EP1948176B1 (es) |
| JP (1) | JP5075832B2 (es) |
| KR (1) | KR20080066030A (es) |
| AR (1) | AR057848A1 (es) |
| AT (1) | ATE493986T1 (es) |
| AU (1) | AU2006312713A1 (es) |
| BR (1) | BRPI0618524A2 (es) |
| CA (1) | CA2628847A1 (es) |
| CU (1) | CU23815A3 (es) |
| DE (1) | DE602006019468D1 (es) |
| DK (1) | DK1948176T3 (es) |
| EC (1) | ECSP088429A (es) |
| IL (1) | IL191010A0 (es) |
| MY (1) | MY144860A (es) |
| NO (1) | NO20082497L (es) |
| NZ (1) | NZ568031A (es) |
| PL (1) | PL1948176T3 (es) |
| PT (1) | PT1948176E (es) |
| SV (1) | SV2009002899A (es) |
| TW (1) | TW200735869A (es) |
| UY (1) | UY29902A1 (es) |
| WO (1) | WO2007054215A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| EP1626714B1 (en) * | 2003-05-20 | 2007-07-04 | Bayer Pharmaceuticals Corporation | Diaryl ureas for diseases mediated by pdgfr |
| EP1663978B1 (en) | 2003-07-23 | 2007-11-28 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| CA2601955C (en) | 2005-03-07 | 2012-07-10 | Bayer Healthcare Ag | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer |
| WO2007087575A2 (en) * | 2006-01-24 | 2007-08-02 | University Of Chicago | Compositions and methods for treating pulmonary hypertension |
| AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| US8680124B2 (en) | 2007-01-19 | 2014-03-25 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
| US20110178137A1 (en) * | 2008-06-25 | 2011-07-21 | Bayer Schering Pharma Aktiengesellschaft | Diaryl urea for treating heart failure |
| EP2621486A1 (en) | 2010-10-01 | 2013-08-07 | Bayer Intellectual Property GmbH | Substituted n-(2-arylamino)aryl sulfonamide-containing combinations |
| EP2723718A1 (en) | 2011-06-24 | 2014-04-30 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
| WO2012177893A2 (en) | 2011-06-24 | 2012-12-27 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
| US8586527B2 (en) * | 2011-10-20 | 2013-11-19 | Jaipal Singh | Cerivastatin to treat pulmonary disorders |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| EP3007689B1 (en) | 2013-01-10 | 2018-03-07 | Pulmokine, Inc. | Non-selective kinase inhibitors |
| JP6483714B2 (ja) | 2013-10-11 | 2019-03-13 | ローレンス エス． ジスマン， | 噴霧乾燥製剤 |
| EP3082428A4 (en) | 2013-12-09 | 2017-08-02 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| US11057446B2 (en) | 2015-05-14 | 2021-07-06 | Bright Data Ltd. | System and method for streaming content from multiple servers |
| BR112019008622A2 (pt) | 2016-10-27 | 2019-07-09 | Pulmokine Inc | método para tratar uma condição |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020065296A1 (en) * | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
| US7928239B2 (en) * | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| SI1478358T1 (sl) * | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
| EP1626714B1 (en) * | 2003-05-20 | 2007-07-04 | Bayer Pharmaceuticals Corporation | Diaryl ureas for diseases mediated by pdgfr |
-
2006
- 2006-10-30 EP EP06828882A patent/EP1948176B1/en not_active Not-in-force
- 2006-10-30 JP JP2008539298A patent/JP5075832B2/ja not_active Expired - Fee Related
- 2006-10-30 KR KR1020087011176A patent/KR20080066030A/ko not_active Ceased
- 2006-10-30 AT AT06828882T patent/ATE493986T1/de active
- 2006-10-30 BR BRPI0618524-0A patent/BRPI0618524A2/pt not_active IP Right Cessation
- 2006-10-30 CA CA002628847A patent/CA2628847A1/en not_active Abandoned
- 2006-10-30 NZ NZ568031A patent/NZ568031A/en not_active IP Right Cessation
- 2006-10-30 WO PCT/EP2006/010405 patent/WO2007054215A1/en not_active Ceased
- 2006-10-30 DE DE602006019468T patent/DE602006019468D1/de active Active
- 2006-10-30 DK DK06828882.8T patent/DK1948176T3/da active
- 2006-10-30 PL PL06828882T patent/PL1948176T3/pl unknown
- 2006-10-30 AU AU2006312713A patent/AU2006312713A1/en not_active Abandoned
- 2006-10-30 MY MYPI20081362A patent/MY144860A/en unknown
- 2006-10-30 US US12/084,659 patent/US20090176791A1/en not_active Abandoned
- 2006-10-30 PT PT06828882T patent/PT1948176E/pt unknown
- 2006-10-31 AR ARP060104766A patent/AR057848A1/es not_active Application Discontinuation
- 2006-11-07 UY UY29902A patent/UY29902A1/es unknown
- 2006-11-09 TW TW095141430A patent/TW200735869A/zh unknown
-
2008
- 2008-04-27 IL IL191010A patent/IL191010A0/en unknown
- 2008-05-06 EC EC2008008429A patent/ECSP088429A/es unknown
- 2008-05-06 SV SV2008002899A patent/SV2009002899A/es unknown
- 2008-05-08 CU CU20080082A patent/CU23815A3/es not_active IP Right Cessation
- 2008-06-03 NO NO20082497A patent/NO20082497L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PT1948176E (pt) | 2011-03-07 |
| CU20080082A7 (es) | 2011-07-11 |
| NZ568031A (en) | 2011-06-30 |
| DE602006019468D1 (de) | 2011-02-17 |
| WO2007054215A1 (en) | 2007-05-18 |
| AU2006312713A1 (en) | 2007-05-18 |
| MY144860A (en) | 2011-11-30 |
| ECSP088429A (es) | 2008-07-30 |
| EP1948176B1 (en) | 2011-01-05 |
| BRPI0618524A2 (pt) | 2011-09-06 |
| NO20082497L (no) | 2008-06-03 |
| CA2628847A1 (en) | 2007-05-18 |
| JP5075832B2 (ja) | 2012-11-21 |
| TW200735869A (en) | 2007-10-01 |
| US20090176791A1 (en) | 2009-07-09 |
| UY29902A1 (es) | 2007-06-29 |
| CU23815A3 (es) | 2012-06-21 |
| DK1948176T3 (da) | 2011-04-18 |
| ATE493986T1 (de) | 2011-01-15 |
| EP1948176A1 (en) | 2008-07-30 |
| KR20080066030A (ko) | 2008-07-15 |
| IL191010A0 (en) | 2009-08-03 |
| JP2009514909A (ja) | 2009-04-09 |
| SV2009002899A (es) | 2009-04-28 |
| PL1948176T3 (pl) | 2011-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057848A1 (es) | Diarilureas para el tratamiento de la hipertension pulmonar | |
| ES2629414T3 (es) | Derivados de tiazol | |
| ES2638980T3 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios | |
| EP2730564B1 (en) | Heterocycle amines and uses thereof | |
| ES2560627T3 (es) | Compuestos y procedimientos para la inhibición de HDAC | |
| US8981084B2 (en) | Oxadiazole HDAC inhibitors | |
| ES2593431T3 (es) | Derivados de piridinil-imidazolona como inhibidores de Pl3-cinasas | |
| AU2013315387B2 (en) | Amino-quinolines as kinase inhibitors | |
| JP6500010B2 (ja) | 新規ピリジン誘導体 | |
| RU2018131539A (ru) | Соединение мочевины, способ его получения и его медицинское применение | |
| PE20090887A1 (es) | DERIVADOS DE 1H-PIRAZOL-[3,4-d]-PIRIMIDINA, 9H-PURINA Y 7H-PIRROL-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASA P70 S6 | |
| CA2522024A1 (en) | Cgrp receptor antagonists | |
| JP2019537594A5 (es) | ||
| RU2016125306A (ru) | Новые пестицидные соединения и применения | |
| CA2971357A1 (en) | Amido thiadiazole derivatives as nadph oxidase inhibitors | |
| ATE463483T1 (de) | 6-substituierte isochinolinderivate als rock-1- inhibitoren | |
| RU2006127455A (ru) | Новые производные пиридина, способ их получения и содержащая их фармацевтическая композиция | |
| PE20110924A1 (es) | Derivados de 2, 4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3 | |
| RU2002125860A (ru) | Новые производные циклического амида | |
| RU2019132155A (ru) | Ингибиторные соединения | |
| PE20050691A1 (es) | Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa | |
| JP2005525324A5 (es) | ||
| GB2609879A (en) | Antagonists of the adenosine A2a receptor | |
| JP2013542204A (ja) | 細菌トポイソメラーゼｉｉ阻害性２−エチルカルバモイルアミノ−１，３−ベンゾチアゾール−５−イル類 | |
| BRPI0714440A2 (pt) | composto inibidor de itpkb, uso do mesmo e composiÇço farmacÊutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |